Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Danielle Shafer"'
Autor:
Danielle Shafer, Amanda B. Kagan, Michelle A. Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader, Dipankar Bandyopadhyay, Daniel Hudson, Heidi Sankala, Caryn Weir, Jeffrey E. Lancet, Steven Grant
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:281-290
Autor:
Mary Steimer, Jessica Leabo, Hongkun Wang, David Heyer, Nancy Bowles, Laura Matthews, Timothy L. Cannon, Raymund Cuevo, William B. Ershler, Danielle Shafer, Sekwon Jang, Angela Pennisi, Amjaad Al-Hussain, Kirby Farrell, John F. Deeken
Publikováno v:
Oncology Issues. 37:20-26
Autor:
Danielle Shafer, Kirby Farrell, Sekwon Jang, John F. Deeken, William B. Ershler, Amjaad Al-Hussain, Jessica Leabo, Timothy L. Cannon, Angela Pennisi, Mary Steimer, David Heyer, Raymund Cuevo, Nancy Bowles, Hongkun Wang, Nancy Addison
Publikováno v:
JCO Oncology Practice. 17:e1286-e1292
PURPOSE:The COVID-19 pandemic has posed significant challenges in the care of patients with cancer, including how to manage outpatients who are COVID-positive but do not require hospitalization. We explored the use of a remote patient monitoring (RPM
Publikováno v:
Blood. 140:6158-6159
Autor:
Arushi Khurana, Danielle Shafer
Publikováno v:
OncoTargets and Therapy. 12:2903-2910
Acute myeloid leukemia (AML) is a clonal heterogenous malignancy of the myeloid cells with a poor prognosis lending itself to novel treatment strategies. TP53 is a critical tumor suppressor and plays an essential role in leukemogenesis. Although TP53
Publikováno v:
Best Practice & Research Clinical Haematology. 32:47-53
Treatment for Hodgkin (HL) and non-Hodgkin's lymphoma (NHL) has changed dramatically in the last fifty years. While there are increasing numbers of long-term survivors, there has been increasing recognition of the long-term toxicities of treatments,
Autor:
Prithviraj Bose, Guillermo Garcia-Manero, Wen Wan, John D. Roberts, Sandeep S. Dave, Elizabeth B. Collins, Steven Grant, Ellen Shrader, Victor Yazbeck, Caryn Weir, Dipankar Bandyopadhyay, Maciej Kmieciak, Amanda Garnett, Danielle Shafer, Mary Beth Tombes, Beata Holkova
Publikováno v:
Leuk Lymphoma
We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4,
Autor:
Eunice S. Wang, Vu H. Duong, Sarah M. Kashanian, Ryan Caddell, Kebede H. Begna, Danielle Shafer, Zeba N. Singh, Kendra Sweet, Aref Al-Kali, Maria R. Baer
Publikováno v:
Annals of hematology. 99(9)
Acute leukemias of ambiguous lineage (ALAL) are rare hematologic malignancies with poor outcomes. Retrospective studies have suggested that acute lymphoblastic leukemia (ALL) regimens are more effective than acute myeloid leukemia (AML) regimens. We
Autor:
Danielle Shafer, Alison A. Ryan, Dipankar Bandyopadhyay, Mark G. Malkin, Paul Dent, Mary Beth Tombes, Ellen Shrader
Publikováno v:
Neuro-oncology Advances
Background Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine the recommended pha
Autor:
Ellen Shrader, Prithviraj Bose, Hannah M. Lee, John D. Roberts, Richard K. Sterling, Mary Beth Tombes, Xiaoyan Deng, Dipankar Bandyopadhyay, Maciej Kmieciak, Paul Dent, Tri K. Nguyen, Andrew Poklepovic, Sarah W. Gordon, William P. McGuire, Scott Matherly, Alison A. Ryan, Danielle Shafer
Publikováno v:
American journal of clinical oncology. 42(8)
Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocell